

**CENTRAL PHARMACEUTICAL  
JOINT STOCK COMPANY 2**

**SOCIALIST REPUBLIC OF VIETNAM**  
**Independence – Freedom – Happiness**

No.: 248 / CV-DPTU2

Hanoi, October 15, 2025

*Regarding: Explanation of profit in business  
operations in 3<sup>rd</sup> Quarter 2025 financial report  
compared to the same period last year, with a  
variance exceeding 10%*

**To:                   - State Securities Commission**  
**- Hanoi Stock Exchange**

Central Pharmaceutical Joint Stock Company 2 (stock code: **DP2**) extends its respectful greetings and gratitude for your agency's recent interest in our Company.

In compliance with Circular No. 96/2020/TT-BTC dated November 16<sup>th</sup>, 2020, of the Ministry of Finance, guiding information disclosure on the securities market:

In the Financial Statements of 3<sup>rd</sup> Quarter 2025 dated 15 October 2025 of the Central Pharmaceutical Joint Stock Company 2, the profit after corporate income tax is VND – 2.399.866.925 for the current period this year, compared to VND -5.821.218.463 for the same period last year.

DP2 would like to explain the profit in its business operations as follows:

- In 3<sup>rd</sup> Quarter 2025, the Company made efforts to restructure products, improve technology, increase labor productivity, reduce the rate of defective products, save costs, and decrease product unit costs.

- In 3<sup>rd</sup> Quarter 2025, sales revenue increased compared to the same period last year, thus resulting in more efficient business operations this quarter.

DP2 respectfully seeks your Agency's assistance.

Sincerely!

**Recipients:**

- As above;
- Archives: General Affairs, Finance & Accounting

**GENERAL DIRECTOR**  
  
**Pharmacist: Le Tien Dung**